Taking advantage of the non-anticoagulant effects of heparin

Greinacher, Andreas

doi:10.1160/th12-01-0054

Search citation statements

Order By: Relevance

Paper Sections

Select...

Review1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the availability of less PF4 to block AT binding and cause heparin neutralization could potentially increase anticoagulant potency [158]. Thus the anti-inflammatory, non-anticoagulant properties of ODSH may be useful for increasing the safety and effectiveness of other anticoagulants [159]. It is a particular advantage that ODSH has already undergone trials demonstrating that it can be safely administered to humans [160].…”

Section: Reviewmentioning

confidence: 99%

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

Prechel

Walenga

2013

Thrombosis J

View full text Add to dashboard Cite

Heparin Induced Thrombocytopenia (HIT) is caused by antibodies that recognize platelet factor 4 (PF4) associated with polyanionic glycosaminoglycan drugs or displayed on vascular cell membranes. These antibodies are elicited by multimolecular complexes that can occur when heparin is administered in clinical settings associated with abundant PF4. Heparin binding alters native PF4 and elicits immune recognition and response. While the presence of heparin is integral to immunogenesis, the HIT antibody binding site is within PF4. Thus HIT antibodies develop and function to cause thrombocytopenia and/or thrombosis only in the presence of PF4. Future emphasis on understanding the biology, turnover and regulation of PF4 may lead to insights into the prevention and treatment of HIT.

show abstract

Section: Reviewmentioning

confidence: 99%